CAY10722 is an inhibitor of sirtuin 3 (SIRT3), a class III HDAC (71% inhibition at 200 μM).
1 SIRT3 is involved in modulating metabolic homeostasis as a NAD
+-dependent protein deacetylase in the mitochondria. SIRT3 functions as either an oncogene or tumor suppressor, depending on cancer cell type.
2,3 High SIRT3 expression in patient-derived esophageal cancer tissues is associated with shorter survival and, in mice, downregulation leads to a lower tumor load.
4 In contrast, low SIRT3 expression in patient-derived breast cancer cells is correlated with shorter survival.
5
